Printer Friendly

Corporate Profile for Boehringer Mannheim Corp., dated Sept. 20, 1996.

--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services.

These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-

Published Date: Sept. 20, 1996

Company Name: Boehringer Mannheim Corp., Therapeutics Division

Address: 101 Orchard Ridge Drive
 Gaithersburg, MD 20878

Main Telephone
 Number: 800/628-2672

Senior VP U.S.
 Therapeutics: John Melville

Manager, Marketing
 Contact: Kevin Kramer
 Business number: 301/216-3733
 e-mail address:


Industry: Pharmaceutical, Biotechnology-0-

Company description: Boehringer Mannheim Corp., Therapeutics Division (BMCT) was established in 1984 in Rockville, Md. BMCT is a division of Boehringer Mannheim Corp. (BMC) located in Indianapolis. With divisions in Diagnostics, Therapeutics, and Biochemicals, BMC is the U.S. member of the Boehringer Mannheim Group of Mannheim, Germany. Boehringer Mannheim has operating divisions in 26 countries, and products available in 150 countries.

After building a drug development group, BMCT sales and marketing launched its first commercial product, ISMO for chronic stable angina, followed in 1994 by DEMADEX, a loop diuretic for the treatment of edema associated with congestive heart failure. Along with DEMADEX and ISMO, BMCT currently markets CARDIAC T Rapid Assay and MICRAL in partnership with BMC Diagnostics.

BMCT moved to Gaithersburg in 1994 and currently employs over 400 in the United States, including a field sales force of 265 representatives. BMCT focuses on research, development and marketing of products in the following therapeutic areas: cardiovascular, renal, oncology, metabolism (bone and diabetes), antivirals/antiinfectives, and gene medicine. The parent company of BMCT was one of the first to develop synthetic pharmaceuticals, formulate early intravenous drugs for cardiac patients, introduce oral anti-diabetic agents, and pioneer biotechnology drug development.

Boehringer Mannheim has built a heritage of quality worldwide with over 140 years of experience. Today, Boehringer Mannheim's principal biotechnology facility in Penzburg, Germany is fully equipped to handle all levels of biotechnological development with more than 1,500 biotechnology products and approximately 200 recombinant products.

Key Statistics

Industry: Biotechnology Segment: Human Therapeutics Ownership: Subsidiary Employees: 400 Revenue: (US $ mil.) Sales: 3.27 billion - 1995

Privately owned

CONTACT: Boehringer Mannheim
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 20, 1996
Previous Article:Corporate Profile for Institutional Shareholder Services, dated Sept. 20, 1996.
Next Article:Corporate Profile for InterDigital, dated Sept. 20, 1996.

Related Articles
GeneMedicine announces second quarter 1995 financial results.
IGEN Adds Boehringer Mannheim Corporation, U.S., President Hubert Rehkaemper and Organon Teknika President Robert Salsmans to Board of Directors.
Cortecs International announces fiscal 1995 year-end results; net sales revenues increase 55% to 7.5 million pounds; consolidated operating loss...
Federal judge orders Boehringer Mannheim to participate in Ostex arbitration.
NeXstar Pharmaceuticals and Boehringer Mannheim to collaborate on antiviral drug development; Boehringer Mannheim makes equity investment in NeXstar.
Corporate Profile for GeneMedicine Inc., dated June 28, 1996.
New clot buster brings a world-leading drugmaker into U.S. spotlight.
Behring Diagnostics and Boehringer Mannheim License HIV-O to Abbott Laboratories.
Sequenom Appoints Former Boehringer Mannheim Executive Delbert F. Foit, Jr. as Chief Operating Officer.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters